Clearside Biomedical announced the acceptance of six abstracts for presentation at the 2025 ARVO meeting. These abstracts cover topics ranging from clinical trial results for CLS-AX, a treatment for wet age-related macular degeneration (AMD), to advancements in suprachoroidal drug delivery technology and training. The company highlights its suprachoroidal drug delivery platform as a transformative approach for treating macular diseases.
This development is important for the ophthalmology field because the data presented at ARVO offers further validation of Clearside’s suprachoroidal injection platform and its potential to become a standard treatment for retinal diseases. Positive clinical trial results for CLS-AX, specifically, could lead to a new, potentially longer-lasting treatment option for wet AMD, a leading cause of vision loss. The research on training programs and segmentation algorithms suggests growing investment in making the procedure more accessible and precise for clinicians.
Key information revealed includes top-line results from the Phase 2b ODYSSEY trial for CLS-AX in wet AMD patients. Additional data will be presented on the safety and durability of CLS-AX. Abstracts also cover a decade-long literature review of suprachoroidal drug delivery, validation of a training program for the injection procedure, analysis of drug formulations, and a new algorithm for imaging the suprachoroidal space. This breadth of research demonstrates Clearside’s commitment to advancing the entire ecosystem surrounding suprachoroidal injections.
The presentation of these abstracts at ARVO marks a significant step for Clearside Biomedical. Positive reception of the ODYSSEY trial results, in particular, could pave the way for a Phase 3 trial and eventual commercialization of CLS-AX, positioning Clearside as a key player in the retinal disease treatment market. Furthermore, continued refinement of the injection procedure and related technologies could lead to wider adoption of suprachoroidal drug delivery as a standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
